ApoGlyx is excited to announce that Anja Holm and Kenneth Stokholm are joining our Board, effective today. Anja brings deep regulatory and veterinary‑medicines expertise from her leadership at Central VetPharma and as former Chair of EMA’s CVMP, while Kenneth brings proven commercial and operational leadership from his tenure as President & CEO of SEVER Pharma Solutions. Together they strengthen our capabilities in regulatory strategy, clinical development, manufacturing partnerships, and corporate governance as we advance innovative Aquaporin inhibitor technologies toward clinical and commercial milestones.
BACKWe use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.